EUVIMEDEUVIMED entdecken
Crossref

Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study

Takashi Nojiri, Akiisa Omura, Hiroshi Nishimura, Hiroshi Uda, Michihito Katayama, Kiyotsugu Iede, Yuki Takeyasu, Utae Katsushima, Hiroshi Okada, Masahiko Higashiyama

Anticancer Research · 2026

DOI: 10.21873/anticanres.18158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Takashi Nojiri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Thoracic Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan; honnnori2003@yahoo.co.jp. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Acrylamides, Aniline Compounds, Lung Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAcrylamidesAniline CompoundsLung NeoplasmsPneumoniaProtein Kinase InhibitorsAntineoplastic AgentsHumansIndolesPyrimidinesMaleRetrospective StudiesFemaleErbB ReceptorsMutationAgedMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

Lung cancerosimertinibpneumonitistoxicity

Substanzen

osimertinibIndolesPyrimidinesAcrylamidesAniline CompoundsErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of General Thoracic Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan; honnnori2003@yahoo.co.jp.
  • Department of General Thoracic Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan.
  • Department of Palliative Medicine, Himeji St. Mary's Hospital, Himeji, Japan.
  • Department of Rheumatology, Higashiosaka City Medical Center, Higashiosaka, Japan.
  • Department of Clinical Oncology, Higashiosaka City Medical Center, Higashiosaka, Japan.
  • Department of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.

Zitieren

APA

Nojiri, T., Omura, A., Nishimura, H., Uda, H., Katayama, M., Iede, K., Takeyasu, Y., Katsushima, U., Okada, H., & Higashiyama, M. (2026). Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study. Anticancer Research. https://doi.org/10.21873/anticanres.18158

Vancouver

Nojiri T, Omura A, Nishimura H, Uda H, Katayama M, Iede K, et al. Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study. Anticancer Research. 2026. doi:10.21873/anticanres.18158

BibTeX
@article{Nojiri2026,
  author = {Nojiri, Takashi and Omura, Akiisa and Nishimura, Hiroshi and Uda, Hiroshi and Katayama, Michihito and Iede, Kiyotsugu and Takeyasu, Yuki and Katsushima, Utae and Okada, Hiroshi and Higashiyama, Masahiko},
  title = {Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18158}
}
Kostenlos starten →